I did some comparisons with other biotec companies that have market caps of 500 to 800 million. Most of them have either NO drug spproved, or no phase 3 drugs, or shallow pipelines, etc... Of the companies that did have one drug approved, either their pipelines were shallow or they had low yearly revenues. So EXEL is either BETTER by comparison or definetely NOT worse or much worse. So what's wrong with our stock that keeps it dropping and dropping day after day after day? Is it possible for a company like EXEL with an approved drug, phase 3 drugs, multiple affiliations with other big pharma, extensive rich pipeline, and 600 million cash.... Is it possible for a company with these characteristics to have a 500 million market cap?
Its possible but not likely as they have decent liquidity to survive and maybe get a winning Lotto ticket. One of the dilemmas is that they are not scoring on big market indications but on smaller indications. Could that change over the next couple of years ? Anything is possible but EXEL has not been able to move the dial much over the past 10 years. Institutional investor interest & expectations are low so if they get lucky the stock could outperform---something it hasn't been able to do for a very long time.
"Could that change over the next couple of years ? Anything is possible but EXEL has not been able to move the dial much over the past 10 years."
Tens years from IND to NDA approval is about average. Any subsequent approval will have the advantage of being a supplemental and a much larger indication. Having the optimum dose determined will work to the company's advantage in attaining those OS endpoints. Comet 2 is a shoo in for attaining its primary endpoint and I feel good about Comet 1 also.